Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Background ST‐segment–elevation myocardial infarction is associated with an intense acute inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade with anakinra significantly reduced the area under the curve for hsCRP ...
Antonio Abbate +28 more
doaj +1 more source
The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats
Brazilian Journal of Pharmaceutical Sciences, 2023 Acrylamide is a neurotoxic compound. Moreover, anakinra is an interleukin-1 (IL-1) receptor antagonist used in rheumatoid arthritis treatment. This study investigated the effect of anakinra on acrylamide-related neuropathy and neuropathic pain ...
Alevtina Ersoy +5 more
doaj +1 more source
Anakinra treatment for refractory cerebral autoinflammatory responses
Annals of Clinical and Translational Neurology, 2022 Refractory cerebral autoinflammatory–autoimmune diseases are often associated with dysregulated innate immunity and are targeted by anakinra, an interleukin‐1 receptor antagonist.
Yoonhyuk Jang +5 more
doaj +1 more source
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Hepatology, EarlyView., 2022 Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr +19 more
wiley +1 more source
Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis
Critical Care Explorations, 2023 OBJECTIVES:. Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required.
Samuel D.J. Dubinsky, PharmD +7 more
doaj +1 more source
PLoS ONE, 2023 BackgroundIn patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death.
Francesco Vladimiro Segala +8 more
doaj +1 more source
Interleukin-1 blockade in recently decompensated systolic heart failure: study design of the recently decompensated heart failure anakinra response trial (RED-HART) [PDF]
, 2015 Heart Failure (HF) is a clinical syndrome characterized by dyspnea, fatigue, and poor exercise capacity due to impaired cardiac function. The incidence of HF is increasing and represents the leading cause of hospitalization in the United States among ...
Abbate Antonio +8 more
core +1 more source
Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. [PDF]
PLoS ONE, 2013 IL-1 receptor antagonist anakinra is usually highly efficient in Schnitzler syndrome (SS), a rare inflammatory condition associating urticaria, fever, and IgM monoclonal gammopathy.
David Launay +9 more
doaj +1 more source
Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) [PDF]
, 2017 Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-firmed HF cases in the United States. However, there are no highly effective evidence-basedtreatments currently available for these patients.
Abbate, Antonio +10 more
core +1 more source
Anakinra Therapy for Non-cancer Inflammatory Diseases
Frontiers in Pharmacology, 2018 Interleukin-1 (IL-1) is the prototypical inflammatory cytokine: two distinct ligands (IL-1α and IL-1β) bind the IL-1 type 1 receptor (IL-1R1) and induce a myriad of secondary inflammatory mediators, including prostaglandins, cytokines, and chemokines. IL-
Giulio Cavalli +3 more
doaj +1 more source